Department of Neurology, University Hospital Ulm, Ulm, Germany.
German Centre for Neurodegenerative Diseases (DZNE), Ulm, Germany.
J Neural Transm (Vienna). 2024 Oct;131(10):1209-1216. doi: 10.1007/s00702-024-02777-z. Epub 2024 May 14.
Advanced Parkinson´s disease (PD) is often complicated by fluctuations of disability depending on plasma levels of levodopa. For most patients OFF phases with worsening of tremor and immobility, but also pain, depression, autonomic symptoms are troublesome. While adjustments of levodopa administrations can relief such fluctuations for some time, "on demand" therapies become more and more important. These "on demand" therapies should provide fast and efficacious relief. During the past years, new options for on demand therapies in PD-associated OFF episodes have been developed, including new formulations of levodopa and apomorphine to provide fast and readily accessible on demand treatment. In this narrative review, the challenges of the treatment of PD-associated fluctuations and OFF states are addressed, with a special focus on sublingual apomorphine (SL-APO) including the results from recent clinical trials.
晚期帕金森病(PD)常因血浆左旋多巴水平而出现波动,导致残疾程度变化。对于大多数患者来说,停药期会出现震颤和运动不能加重、疼痛、抑郁、自主神经症状等问题。虽然调整左旋多巴的给药可以在一段时间内缓解这些波动,但“按需”治疗变得越来越重要。这些“按需”治疗应该提供快速有效的缓解。在过去的几年中,针对 PD 相关停药期的“按需”治疗新方案已经得到发展,包括左旋多巴的新配方和阿扑吗啡,以提供快速且易于获得的按需治疗。在本综述中,我们探讨了治疗 PD 相关波动和停药期的挑战,并特别关注舌下阿扑吗啡(SL-APO),包括最近临床试验的结果。